Sanofi's strategy in the insulin market might provide a blueprint for other drugmakers facing an unsustainable business model and lack of capital, writes Daniel Hoffman. The company's iBGStar glucose monitor connects to a smartphone, linking patients to their health care providers and positioning Sanofi as a comprehensive diabetes company. "At the least, the program represents an easily discernible effort to do well by doing good, and that's not a bad approach for pharma to take," Hoffman writes.

Related Summaries